Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

224.92 USD -2.60 (-1.14%)
Official Closing Price Updated: 7:59 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,453,500
Open 230.31
Bid (Size) 224.40 (2)
Ask (Size) 225.00 (1)
Prev. Close 227.52
Today's Range 223.62 - 230.31
52wk Range 177.05 - 276.69
Shares Outstanding 661,706,000
Dividend Yield 2.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
Data From Investigational Therapy Tezepelumab Phase 3 NAVIGATOR Trial in Patients With Severe Asthma Presented at the American Academy of Asthma Allergy & Immunology Annual Meeting 
From PR Newswire
Amgen To Present At The Cowen 41st Annual Healthcare Conference
Amgen (NASDAQ:AMGN) will present at the Cowen 41st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday, March 4, 2021. Murdo Gordon, executive vice president of Global Commercial... 
From PR Newswire

Performance

YTD
-0.77%
-0.77%
1 Month
-10.41%
-10.41%
3 Month
+0.05%
+0.05%
6 Month
-11.14%
-11.14%
1 Year
+10.53%
+10.53%

More News

Read More
Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting
From PR Newswire
Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis
From PR Newswire
FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
From PR Newswire
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
From Business Wire News Releases
AstraZeneca/Amgen's Tezepelumab Reduces Asthma Exacerbations, Phase 3 Trial Shows
Tags Benzinga AMGN Phase 3 Trial
From Benzinga
Should Investors Be Watching These Top Coronavirus Stocks Right Now?
Tags Market News
From Stockmarket.com
How Does Amgen's Debt Look?
Tags Markets Intraday Update News
From Benzinga
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
Tags Market News BZI/AUOA MRKR
From Benzinga
Why Turning Point Is Turning Heads
Tags Market News TPTX AMGN
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.